Key facts
- Alloy Therapeutics’s last known valuation is $1.0B (Apr 2026).
- It has raised $174.0M across 3 recorded rounds; the latest was Early Stage VC ($30.0M) in Mar 2026.
- Notable investors include Gaingels, Founders Fund, 8VC, Calm Ventures, OurCrowd — 24 tracked in total.
- Alloy Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Apr 2026 ($30.0M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Alloy Therapeutics
Funding rounds
3 roundsAbout Alloy Therapeutics
Developer of biotechnology platforms intended for drug discovery and development. The company's platform provides engineered biological systems, data-driven systems, antibody discovery capabilities, and integration with machine learning techniques to support target identification, optimization, and preclinical research workflows, enabling pharmaceutical and biotechnology organizations to improve efficiency and reduce uncertainty in therapeutic development processes.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 137
- Website
- alloytx.com/
- Ownership
- Privately Held (backing)
Alloy Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alloy Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alloy Therapeutics in its N-PORT filings yet. We sweep new filings monthly.